In a retrospective chart review, IV ketamine led to in a 50% reduction in pain at discharge, with “nearly two-thirds” of patients having no recurrence within 30 days, lead investigator Scott Rosenthal, [instructor/fellow of pediatrics, Section of Neurology] from the University of Colorado Anschutz Medical Campus, Aurora, noted. Rosenthal reported the findings (Abstract S20.010) on April 15 at the American Academy of Neurology 2024 annual meeting.
CU Anschutz
Administrative Pavilion
13123 E. 16th Ave.
B065
Aurora, CO 80045